Cizzle Bio, Inc.

11/03/2026

Take our quick lung cancer myth check.

Vote in the poll, then swipe to see the answer.



True or false?
Only people who smoke get lung cancer.

10/22/2026

Dallas–Fort Worth healthcare providers can access CIZ1B test clinical evidence, patient considerations, and ordering setup information.

Provider resources:
https://go.cizzlebio.com/7y9aRy

10/21/2026

Cizzle Bio is working to support earlier lung cancer detection conversations throughout Texas. The CIZ1B test is available through licensed healthcare providers in Dallas–Fort Worth and San Antonio.

Learn more:
https://go.cizzlebio.com/YQu6cM

10/20/2026

A familiar voice. An important conversation. A shared focus on earlier lung cancer detection.

Dr. Lary A. Robinson, Director of the Lung Cancer Early Detection (LEAD) Center at Moffitt Cancer Center and principal investigator of Cizzle Bio’s CIZ1B clinical validation study at Moffitt, is featured in a recent Fox News article examining why lung cancer can go undetected—and the importance of early detection.

Dr. Robinson highlights a critical challenge: early-stage lung cancer often causes no symptoms.

The article also explores the potential future of blood-based testing. Yale thoracic surgeon Dr. Daniel Boffa shares his hope for the potential role of a blood test in early detection.

“I'm hoping that within four or five years, a screening CT scan will only be confirmatory after they have a positive blood test done at your doctor's office.”

For Cizzle Bio, the broader interest in blood-based biomarkers reinforces the importance of the research behind CIZ1B.

Our CIZ1B Biomarker Blood Test for Lung Cancer is being evaluated at Moffitt Cancer Center in patients with identified lung nodules, including its potential to help distinguish malignant from benign nodules. This research is helping build evidence about where CIZ1B may add meaningful information to physician-led lung cancer assessment.

The goal: better information to support informed clinical decisions, alongside established tools and care pathways.

Read the full article: https://www.foxnews.com/health/lung-cancer-grow-silently-years-qualifies-screening

Only 15% of eligible Americans get screened for lung cancer, translating to tens of thousands of preventable deaths every year, doctors warn.

10/16/2026

Questions about lung cancer risk deserve an informed conversation. If you live in the San Antonio area, consider asking your healthcare provider about your personal risk factors, LDCT screening eligibility, and whether additional assessment may be appropriate.

Patient information:
https://go.cizzlebio.com/dsuWuE

10/15/2026

San Antonio-area healthcare providers can review clinical information and ordering setup steps for the CIZ1B Biomarker Blood Test for Lung Cancer.

Provider resources:
https://go.cizzlebio.com/rBaktj

10/13/2026

Licensed healthcare providers in Dallas–Fort Worth can begin CIZ1B test ordering setup and receive follow-up guidance covering onboarding, ordering, specimen collection, and results access.

Provider information:
https://go.cizzlebio.com/BQvp7M

10/13/2026

Moving cancer research forward takes collaboration.

Dr. Steven T. Rosen, Scientific Advisor to Cizzle Bio, joined leading cancer researchers on October 6 for a panel discussion at the Global Cancer Research & Innovation Symposium (GCRIS) in New York City.

His participation highlights the scientific expertise guiding our work on the CIZ1B Biomarker Blood Test for Lung Cancer—designed to complement standard-of-care diagnostics and support clinical decision-making.

Read the full press release for Dr. Rosen’s perspective and the latest updates on CIZ1B research and availability: https://go.cizzlebio.com/fXJhNW


Association for Value-Based Cancer Care

/PRNewswire/ -- Dr. Steven T. Rosen, scientific advisor to Cizzle Bio and a globally recognized leader in cancer research and translational medicine, joined...

10/13/2026

LDCT and biomarker blood testing provide different types of information. The CIZ1B test is designed to complement established clinical approaches—not replace them.

Read the article:
https://go.cizzlebio.com/MM4Vn4

10/12/2026

We’re looking forward to the 4th Annual Doc-to-Doc Meet and Greet on October 14 at the McKenna Events Center in New Braunfels.

This event brings together physicians and healthcare professionals from across the Hill Country to build stronger referral relationships, improve communication and support better continuity of care for patients.

Attending? Stop by to meet the Cizzle Bio team and learn more about our work in early cancer detection.

Learn more: https://go.cizzlebio.com/URCnXK


Texas Academy of Family Physicians

Cizzle Bio will participate in the 4th Annual Doc-to-Doc Meet and Greet, connecting with Hill Country physicians and healthcare professionals in New Braunfels.